William Blair analyst Myles Minter has maintained their bullish stance on IONS stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Myles Minter’s rating is based on Ionis Pharmaceuticals’ promising financial outlook and strategic advancements. The company is poised for significant revenue growth, with a mix of commercial-stage royalty-based and wholly owned product revenue streams that are expected to reach over $5 billion at peak. This growth is supported by the potential positive outcomes from up to six Phase III clinical studies anticipated by the end of 2026, which could further enhance top-line growth.
Minter also highlights Ionis’s strong financial position, with a projected $2.0 billion on the balance sheet, and the expectation to achieve cash flow positivity by 2028. Additionally, the company’s innovative pipeline, including Tryngolza for severe hypertriglyceridemia, presents a compelling case for early adoption in the market, assuming regulatory approval. These factors collectively contribute to the Buy rating, reflecting confidence in Ionis’s ability to deliver long-term value to shareholders.
In another report released today, Needham also maintained a Buy rating on the stock with a $78.00 price target.